iparomlimab + regorafenib

Iparomlimab + regorafenib is an investigational combination therapy consisting of iparomlimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, and regorafenib, an oral multi-kinase inhibitor. Iparomlimab functions as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to reactivate T-cell mediated anti-tumor immunity. Regorafenib inhibits a broad range of protein kinases involved in tumor angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR). This combination is being explored for its potential synergistic effects, where regorafenib-mediated modulation of the tumor microenvironment and angiogenesis may enhance the efficacy of PD-1 blockade. Clinical development is notably being led by Peking Union Medical College Hospital for the treatment of advanced solid tumors, including anal squamous cell carcinoma, peritoneal mesothelioma, and peritoneal metastatic cancer.

Other names

QL1604 + regorafenib